New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Editas Medicine, Inc. (EDIT) vs Prelude Therapeutics Incorporated (PRLD)

Editas Medicine, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Editas Medicine, Inc. and Prelude Therapeutics Incorporated are of similar size ($263.9M and $260.5M). Editas Medicine, Inc. has the higher net margin (−145.0% vs −247.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Editas Medicine, Inc. leads on 7 and Prelude Therapeutics Incorporated on 6.

Valuation

Metric EDIT PRLD Biotechnology median
P/E n/m n/m 8.49
P/S 5.02 15.44 8.56
P/B 2.96 2.68 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 1.21 8.95 8.00
Earnings yield (38.18%) (18.32%) (35.81%)
Free cash flow yield (44.01%) (8.40%) (25.41%)

Profitability

Metric EDIT PRLD Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (151.71%) (283.92%) 0.00%
Net margin (144.95%) (247.12%) 0.00%
Free cash flow margin (221.15%) (129.68%) 0.00%
Return on equity (147.44%) (58.36%) (51.58%)
Return on assets (34.30%) (39.45%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric EDIT PRLD Biotechnology median
Revenue growth (TTM) 7.42% — 7.20%
EPS growth (last fiscal year) 37.50% 23.21% 29.04%
Revenue growth, 5-year CAGR (14.89%) — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric EDIT PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.82 4.20 4.79
Net debt to EBITDA 0.94 1.00 1.01

Dividend

Metric EDIT PRLD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EDIT PRLD Biotechnology median
Market cap 263.92m 260.48m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack